	Adjuvant Systemic Therapies After Nephrectomy for Renal Cell Carcinoma: A Bayesian Network Meta-Analysis and Multi-Criteria Benefit-Risk Assessment. Target Oncol Yajima S, Okumura G, Yoshida S, Fukushima H, Sato H, Hirakawa A, Kijima T, Masuda H, Fujii Y. PMID: 42892667 [PubMed - as supplied by publisher]
	Qualitative study on barriers and facilitators to genetic testing in Hispanic patients with prostate cancer. Prostate Cancer Prostatic Dis Chebli P, Sanchez Nolasco T, Rangel Camacho M, Byrne N, Giri VN, Vadaparampil ST, Loeb S. PMID: 42892630 [PubMed - as supplied by publisher]
	Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study. Urol Oncol Titus RS, Velasquez EL, Mundra V, Riveros C, Ranganathan S, Nguyen DD, Singh A, Porika A, Kaushik D, Patel KV, Efstathiou E, Wallis CJD, Satkunasivam R. PMID: 42892580 [PubMed - as supplied by publisher]
	Incidence and predictors of prolonged opioid use following nephrectomy for renal cell carcinoma: A national claims-based study. Urol Oncol Esen B, Lahiji R, Patil D, Luke W, Mumford S, Landrum KR, Ramacciotti LS, Nabavizadeh R, Hajiha M, Grajales V, Joshi SS, Narayan VM, Ogan K, Master VA. PMID: 42892579 [PubMed - as supplied by publisher]
	Restricted mean survival time-based network meta-analysis of first-line therapies for metastatic clear cell renal cell carcinoma. Urol Oncol McGrath J, Johnson K, Hakam N, Venkatesh A, Ishiyama Y, Metzner T, Balaji KC. PMID: 42892578 [PubMed - as supplied by publisher]
	Individual and Mixed Urinary Trace Metal Exposures and their Associations with Prostate Cancer in Tanzania: A Case-Control Study Using BKMR. Environ Toxicol Pharmacol Njale E, Mahugija JAM, Shilla DJ. PMID: 42892537 [PubMed - as supplied by publisher]
	Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer from the ARASENS trial. Eur J Cancer Maiorano BA, Smith MR, Hussain M, Saad F, Tombal B, Sternberg CN, Mohamed AF, Dissanayake M, Moscovici M, Verholen F, Kuss I, Fizazi K. PMID: 42892235 [PubMed - as supplied by publisher]
	Digital supportive care in prostate cancer: a systematic review. Support Care Cancer Paterson C, Coro D, Morris JN, Turner MR, Perrotta N, Godfrey M, Robertson A, Christina J. PMID: 42891837 [PubMed - indexed for MEDLINE]
	Geographic disparities and temporal trends in aggressive prostate cancer: a SEER population-based analysis (2004-2022). Cancer Causes Control Xu Y, Singh A, Li E, Zaorsky NG, Geyer N, Yang Y, Yang Y, McDonald AC, Zhang L, Wang M. PMID: 42891738 [PubMed - indexed for MEDLINE]
	Radiological lymphoceles and clinically relevant lymphatic complications after retroperitoneal lymph node dissection for testicular cancer: a longitudinal imaging study. Abdom Radiol (NY) Lenart S, Wafa H, Pichler U, Aigner F, Gruber L, Hoeller A, Klinglmair G, Peschel R, Mikulits C, Resch I, Pichler R. PMID: 42891703 [PubMed - as supplied by publisher]
	Small Cell Neuroendocrine Carcinoma of the Bladder With Lymph Node Metastases: A Case Report. Cureus El Ourdi S, Zouiten O, Afani L, El Fadli M, Belbaraka R. PMID: 42891345 [PubMed]
	Microbiome-urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation. IMetaOmics Xu H, Li Z, Yang L, Zheng J, Li W, Liao R, Huang W, Sun B, Li Z, Ma C, Yang X, Wang Z, Zhao J, Cheng B, Wu P. PMID: 42891336 [PubMed]
	Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304). EClinicalMedicine Law CK, Stockler MR, Martin AJ, Davis ID, Sweeney CJ, Morton RL. PMID: 42890411 [PubMed]
	Multiparametric MRI-based habitat and peritumoral radiomics integrating semi-automated segmentation for preoperative prediction of high-grade prostate cancer: a dual-center study. Front Oncol Hua D, Ma L, Ji X, Huang L, Zhao Y, Shen W. PMID: 42890019 [PubMed]
	From inherited susceptibility to tumor state: toward a stage-aware architecture for genomic risk stratification in prostate cancer. Front Genet Zheng Z, Yang X, Ou M, Chen Y, Gan D. PMID: 42889514 [PubMed]
	Successful management of synchronous prostate adenocarcinoma and lung squamous cell carcinoma with sintilimab and ADT in a frail elderly patient with bronchiectasis: a case report. Front Immunol Huang Y, Zhan W, Su T, Liu Y. PMID: 42889325 [PubMed - indexed for MEDLINE]
	NEITHER study: NICE versus EAU inconsistent triage, expenses and reliability in non-high-risk non-muscle invasive bladder cancer surveillance. BJUI Compass Ibrahim Y, Ribeiro L, Heelan M, Spazzapam M, Macaskill F, Fernando K, Ahmed A, Hussien A, Gad M, Chakravarti S, Mokbel S, Nair R, Thurairaja R, Khan MS, Abughanem Y, Mensah E. PMID: 42889172 [PubMed]
	Integrated network toxicology, transcriptomic, and Mendelian randomization analyses explore potential molecular links between acrylamide exposure and clear cell renal cell carcinoma. Medicine (Baltimore) Deng S, Wang S, Zeng Z, Li T, Zou L, Zhou Y, Lei L, Zhou T. PMID: 42888631 [PubMed - indexed for MEDLINE]
	Diagnosis of prostate cancer by multi-modal ultrasound imaging. Medicine (Baltimore) Li J, He K, Zhang H, Hu D, Wei X, Luo L. PMID: 42888615 [PubMed - indexed for MEDLINE]
	Development and validation of a ferroptosis and metabolic reprogramming gene signature for risk stratification in bladder urothelial carcinoma: A retrospective multicohort study. Medicine (Baltimore) Ma Y, Zhang Z, Tang L, Li Q, Zhao Y. PMID: 42888597 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 182253

Page 1 of 9113



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy